News
$Seelos Therapeutics(SEEL.US$ Seelos Therapeutics Selects SLS-002 (Intranasal Racemic Ketamine) For Inclusion In The U.S. Department Of Defense's Adaptive Platform Trial To Evaluate Potential Treatments For Post-traumatic Stress Disorder
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment